Format

Send to

Choose Destination
Neurol Res. 2017 Mar;39(3):231-238. doi: 10.1080/01616412.2017.1281195. Epub 2017 Jan 20.

Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease.

Author information

1
a Department of Environmental and Molecular Medicine , Mie University Graduate School of Medicine , Tsu , Japan.
2
b Graduate School of Regional Innovation Studies , Mie University , Tsu , Japan.
3
c Department of Dementia Prevention and Therapeutics , Mie University Graduate School of Medicine , Tsu , Japan.
4
d Department of Neurology , Mie University Graduate School of Medicine , Tsu , Japan.

Abstract

OBJECTIVES:

Alzheimer's disease (AD) is the most common cause of dementia in elderly persons. Since the pathology of AD develops slowly from a preclinical or early phase into a fully expressed clinical syndrome, at the time of diagnosis the disease has been progressing for many years. To facilitate the early diagnosis of AD, we performed protein profiling of blood in patients with mild AD as defined by the Functional Assessment Staging (FAST) scale.

METHODS:

Plasma samples from mild AD patients and healthy controls were analyzed using two-dimensional differential gel electrophoresis (2D-DIGE) combined with matrix-assisted laser desorption ionization time-of-flight tandem mass spectrometry (MALDI-TOF/TOF/MS) followed by peptide mass fingerprinting.

RESULTS:

Three downregulated proteins were identified: apolipoprotein A-1, alpha-2-HS-glycoprotein, and afamin. Two proteins, including apolipoprotein A-4 and fibrinogen gamma chain, were upregulated in mild AD patients.

DISCUSSION:

Our results suggest that altered expression levels of these proteins in plasma may yield candidate biomarkers for the early diagnosis of AD.

ABBREVIATIONS:

AD, Alzheimer's disease; FAST, Functional Assessment Staging; 2D-DIGE, two-dimensional differential gel electrophoresis; MALDI-TOF/TOF/MS, matrix-assisted laser desorption ionization time-of-flight tandem mass spectrometry; CSF, cerebrospinal fluid; Aβ, amyloid beta; MMSE, Mini Mental State Examination; MRI, magnetic resonance imaging; NINCDS-ADRDA, National Institute for Neurological Diseases and Stroke/Alzheimer's Disease and Related Disorders Association; CHAPS, 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate; DTT, dithiothreitol; SDS-PAGE, SDS-polyacrylamide gel electrophoresis; DIA, differential in-gel analysis; BVA, biological variation analysis; CBB, Coomassie brilliant blue; 2DE, two-dimensional gel electrophoresis; TFA, trifluoroacetic acid; ACTH, adrenocorticotropic hormone; Apo A-1, apolipoprotein A-1; AHSG, alpha-2-HS-glycoprotein; Apo A-4, apolipoprotein A-4; MCI, mild cognitive impairment.

KEYWORDS:

2D-DIGE; Alzheimer’s disease; biomarkers; plasma; proteomics

PMID:
28107809
DOI:
10.1080/01616412.2017.1281195
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center